dose escalation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
According to legends, the history of theriac begins with the king Mithridates VI of Pontus who experimented with poisons and antidotes on his prisoners. His numerous toxicity experiments eventually led him to declare that he had discovered an antidote for every venomous reptile and poisonous substance. He mixed all the effective antidotes into a single one, mithridatium or mithridate. Mithridate contained opium, myrrh, saffron, ginger, cinnamon and castor, along with some forty other ingredients. When the Romans defeated him, his medical notes fell into their hands and Roman medici began to use them. Emperor Nero's physician Andromachus improved upon mithridatum by bringing the total number of ingredients to sixty-four, including viper's flesh, a mashed decoction of which, first roasted then well aged, proved the most constant ingredient. Lise Manniche, however, links the origins of theriac to the ancient Egyptian kyphi recipe, which was also used medicinally. Greek physician Galen devoted a whole book, Theriaké, to theriac, documenting many notable theriacs such as Philonium. One of his patients, Roman emperor Marcus Aurelius, took it on a regular basis. In 667, ambassadors from Rûm presented the Emperor Gaozong of the Tang dynasty in China with a theriac. The Chinese observed that it contained the gall of swine, was dark red in colour and the foreigners seemed to respect it greatly. The Tang pharmacologist Su Kung noted that it had proved its usefulness against "the hundred ailments".
Metenolone and its esters are banned from use in sports governed by the World Anti-Doping Agency. The NBA and NBPA also banned the use of metenolone and its esters under the Anti-Drug Program. There are known cases of doping in sports with metenolone esters by professional athletes.
=== Surgery === If the TIA affects an area that is supplied by the carotid arteries, a carotid ultrasound scan may demonstrate stenosis, or narrowing, of the carotid artery. For people with extra-cranial carotid stenosis, if 70-99% of the carotid artery is clogged, carotid endarterectomy can decrease the five-year risk of ischemic stroke by approximately half. For those with extra-cranial stenosis between 50 and 69%, carotid endarterectomy decreases the 5-year risk of ischemic stroke by about 16%. For those with extra-cranial stenosis less than 50%, carotid endarterectomy does not reduce stroke risk and may, in some cases, increase it. The effectiveness of carotid endarterectomy or carotid artery stenting in reducing stroke risk in people with intracranial carotid artery stenosis is unknown. In carotid endarterectomy, a surgeon makes an incision in the neck, opens up the carotid artery, and removes the plaque occluding the blood vessel. The artery may then be repaired by adding a graft from another vessel in the body or a woven patch. In patients who undergo carotid endarterectomy after a TIA or minor stroke, the 30-day risk of death or stroke is 7%. Carotid artery stenting is a less invasive alternative to carotid endarterectomy for people with extra-cranial carotid artery stenosis. In this procedure, the surgeon makes a small cut in the groin and threads a small flexible tube, called a catheter, into the patient's carotid artery. A balloon is inflated at the site of stenosis, opening up the clogged artery to allow for increased blood flow to the brain.
=== Viscosity === If the evolent has high viscosity, it would produce a high backpressure. Consequently, low-viscosity evolents are preferred. IPA is strongly eluting, but also very viscuous, which results in high backpressures. ACN and MeOH are less viscous than IPA, although a mixture of 50:50 percent of MeOH:water is also very viscous. In general, as the ratio of organic solvent:water increases from 0:1 to 1:0, the viscosity increases, then decreases again. In general, backpressure increased when the flow rate is increased, the mobile phase temperature is lowered, or the stationary phase particle size is increased.
=== Angiotensin III === Amino acid sequence: Asp | Arg-Val-Tyr-Ile-His-Pro-Phe Angiotensin III, along with angiotensin II, is considered an active peptide derived from angiotensinogen. It is formed by removing an amino acid from angiotensin II by glutamyl aminopeptidase A, which cleaves the N-terminal Asp residue. Angiotensin III has 40% of the pressor activity of angiotensin II, but 100% of the aldosterone-producing activity. It increases mean arterial pressure. Activation of the AT2 receptor by angiotensin III triggers natriuresis, while AT2 activation via angiotensin II does not. This natriuretic response via angiotensin III occurs when the AT1 receptor is blocked.
Sources: en.wikipedia.org
Nvidia revealed the GeForce GTX 1080, the world's first graphics card with DisplayPort 1.4 support on 6 May 2016. AMD followed with the Radeon RX 480 to support DisplayPort 1.3/1.4 on 29 June 2016. The Radeon RX 400 series will support DisplayPort 1.3 HBR and HDR10, dropping the DVI connector(s) in the reference board design. In February 2017, VESA and Qualcomm announced that DisplayPort Alt Mode video transport will be integrated into the Snapdragon 835 mobile chipset, which powers smartphones, VR/AR head-mounted displays, IP cameras, tablets and mobile PCs.
A protein subunit is a polypeptide chain or protein molecule that assembles (or "coassembles") with other protein molecules to form a protein complex. Large assemblies of proteins such as viruses often use a small number of types of protein subunits as building blocks. A key step in creating a recombinant protein vaccine is the identification and isolation of a protein subunit from the pathogen which is likely to trigger a strong and effective immune response, without including the parts of the virus or bacterium that enable the pathogen to reproduce. Parts of the protein shell or capsid of a virus are often suitable. The goal is for the protein subunit to prime the immune system response by mimicking the appearance but not the action of the pathogen. Another protein-based approach involves self‐assembly of multiple protein subunits into a virus-like particle (VLP) or nanoparticle. The purpose of increasing the vaccine's surface similarity to a whole virus particle (but not its ability to spread) is to trigger a stronger immune response. Protein subunit vaccines are generally made through protein production, manipulating the gene expression of an organism so that it expresses large amounts of a recombinant gene. A variety of approaches can be used for development depending on the vaccine involved. Yeast, baculovirus, or mammalian cell cultures can be used to produce large amounts of proteins in vitro. Protein-based vaccines are being used for hepatitis B and for human papillomavirus (HPV).
== Technology life cycle == Silica monoliths have only been commercially available since 2001, when Merck began their Chromolith campaign. The Chromolith technology was licensed from Soga and Nakanishi's group at Kyoto University. The new product won the PittCon Editors’ Gold Award for Best New Product, as well as an R&D 100 Award, both in 2001. Individual monolith columns have a life cycle that generally exceeds that of its particulate competitors. When selecting an HPLC column supplier, column lifetime was second only to column-to-column reproducibility in importance to the purchaser. Chromolith columns, for example, have demonstrated reproducibility of 3,300 sample injections and 50,000 column volumes of mobile phase. Also important to the life cycle of the monolith is its increased mechanical robustness; polymeric monoliths are able to withstand pH ranges from 1 to 14, can endure elevated temperatures, and do not need to be handled delicately. “Monoliths are still teenagers,” affirms Frantisec Svec, a leader in the field of novel stationary phases for LC.
Directed by Sheila Hayman, made by Uden Associates 8 November Rebuilding Berlin, how German telecommunication and electrical engineers found great difficulty in connecting the infrastructure and technology of East and West Berlin, which were largely totally incompatible, and why the two technological systems were so different; East and West Germany were founded in 1953; the trains in East (Deutsche Reichsbahn or DR) and West Germany ran on electric motors that worked in opposite ways; Erich Kratky of Berliner Verkehrsbetriebe (former West Berlin Public Transport) and how East Berlin drivers had 60% of those in West Berlin; Mahlow station, on the S2 line on the Berlin S-Bahn, was completely rebuilt in 1991, opening on 31 August 1992; before 1989, West Berlin could not connect to any neighbouring electrical power networks, so had to make all of its own power itself, by nine power stations; in 1992 West Berlin could not make enough electrical power;Jürgen Beyer of the East Berlin Electricity Board; in 1992 East and West Germany could not connect their electricity systems together; Klaus Krämer of the West Berlin Electricity Board, and how East German load frequency control (LFC) was not good enough for West Germany; East German power stations were polluting; Müggelsee in East Berlin; East Berlin had natural gas - from Russia - but West Berlin did not have natural gas, and had to produce its own gas from processing, and there were many more gas leaks in East Berlin, run by the Berlin Gas Board, and British Gas plc was installing most of the new plastic gas mains in East Berlin; one fifth of housing in East Berlin was uninhabitable, due to lack of renovation and unsafe electrical wiring; much housing in East Berlin did not have any bathrooms; the post system in East Berlin was three times slower than West Berlin, as it was all sorted by hand, and mail hand to be sent in standard envelopes only, in East Germany - the two post systems were incompatible, and East and West Germany had totally different postcode systems, although both had four digits, so a letter was put in front of each Deutsche Post postcode, to show if it was an East or West German postcode; in 1952, telephone connections between East and West Germany were stopped, but four lines were installed in 1972; the East German telephone exchanges were all mechanical, and could not transmit any digital communications; one in ten people in East Berlin had a phone - telecommunications in East Berlin were hopeless and expensive; in 1992 Deutsche Telekom connected East and West Berlin, and the price would be a local call, not the price of an international call, under the phrase Wir schaffen Verbingdungen; not only were East German telecommunications often impossible, but the Stasi secret police were listening in to most calls; Rudolf Reichel of the former East German Economic Institute; science research in East Germany had been greatly restricted; Volker Hassemer; East Germans viewed West Germans as selfish, and West Germans viewed East Germans as backward. Narrated by Su-Lin Looi, directed by Cosima Dannoritzer, produced by Karl Sabbagh, made by Skyscraper Productions 15 November 21st Century Jet, how the Boeing 777 moved from the drawing board to manufacture in 1992, with the innovative new method called CATIA; the Boeing 777 was the largest jet aircraft to have been developed mostly by computer, with assembly beginning in January 1993; there were 10,000 people in the 777 programme, who met the managers in a weekly meeting; meeting the needs of Robert Crandall of American Airlines, and competition from the new Airbus A340; parts of the tail were built in Australia; the nose cone and flaps were made in Italy; the landing gear was made in Canada, the US, and France; parts of the wing ribs and passenger doors were made in Japan; the nose landing gear door was made in Belfast; some of the electronics was made in England; there were about 230 design teams, from different manufacturers; the CATIA system was a digital mockup; Thomas Gaffney, head of passenger doors; Henry Shomber, one of the chief engineers; John Roundhill, a chief project engineer; United Airlines placed the first order, which started the project; Al Tyler of Aerospace Technologies of Australia (ASTA), who made the 777 rudder - the company became Boeing Australia; John King, Baron King of Wartnaby of British Airways visits to look at legroom for the new 777. Narrated by Simon Prebble, directed by Karl Sabbagh, made by Skyscraper Productions 22 November The Puzzle of HIV, scientists after ten years did not understand how HIV worked; immunologists Anthony Fauci and Max Essex; Angus Dalgleish of St George's, University of London; virologist Stephen S. Morse, and the origination of viruses, and how most pandemics originated in China; Stella Knight of the MRC, and dendritic cells, researched by Brigid Balfour; French immunologist Jean-Claude Ameisen of the Pasteur Institute of Lille; virologist Jonas Salk; Claude Nicolau, and the CD4 glycoprotein. Narrated by Scottish actress Sandra Clark, directed by Nigel Maslin, produced by Chris Haws, made by InCA Productions 29 November The Alpha Link, much of medical understanding of radiation protection and health comes from what occurred in Japan in August 1945. Martin Gardner (1940–93), an epidemiologist, and Professor of Medical Statistics at the University of Southampton, thought that health was affected by working in a nuclear power station, which the British nuclear industry vehemently would not believe. Directed by Vivienne King, made by Box Productions 6 December Toying with the Future, about electronic children's toys, visiting Ocean Software in Manchester; Brian Sutton-Smith of the University of Pennsylvania, and how toys were small replicas of large world events; Eugene F. Provenzo of the University of Miami and how the culture of childhood began in the early 1700s, and how German Friedrich Fröbel developed educational toys in the early 1800s, but it often lacked fun; Meccano Ltd sets, developed by Frank Hornby, launching the international Meccano Guild network of children's mechanical clubs in 1919, publicised by the Meccano Magazine; Richard Gregory, neuropsychologist at the University of Bristol, and his Exploratory Hands-on Science Centre, which closed in 1999, replaced by We the Curious in 2000; toy designer Patrick Rylands; Gary Bracey of Ocean Software; Keith Tinman, computer game musician; Elizabeth Curran of GameTek; Ocean Software designers Ray Coffey, James Higgins and Dawn Drake. Directed by Christopher Rawlence, produced by Debra Hauer, made by Rawlence Hauer Productions 13 December The Elements, a repeat of the 20 October 1991 episode 20 December E.T. Please Phone Earth, about the SETI Institute, with Prof Philip Morrison, a professor of physics at MIT, who played a starring if not dangerous role in the Manhattan Project; Jill Tarter at the Hat Creek Radio Observatory in California; Dr John Billingham, a British medical doctor at the Ames Research Center in California; Prof Antony Hewish of the University of Cambridge, who discovered pulsars in 1967; Frank Drake, and his work at the National Radio Astronomy Observatory in Green Bank, West Virginia; Barney Oliver of SETI; David Blair of the University of Western Australia; Paul Horowitz of Harvard University; the Ohio State University Radio Observatory (known as Big Ear) and its 1977 Wow! signal; Jack Cohen; chemist Stanley Miller and his 1953 experiment; blind SETI investigator Kent Cullers; and biologist Jared Diamond from UCLA. Jointly made with ABC of Australia, narrated by Heather Couper, directed by Richard Smith, produced by Stuart Carter, made by Pioneer Productions
Sources: en.wikipedia.org
==== Nylon netting ==== The open structure of nylon net makes it the most commonly used sheer overlay fabric. One of its most notable attributes is that it does not unravel or fray. Nylon is susceptible to light-catalyzed degradation, thus the lifespan of the nylon may contradict its purpose if the artifact is being exhibited. Textile Conservators may use either heat set or bobbinet netting, both of which do not fray but are susceptible to degradation and reactions from light. Netting may be used together with a backing fabric.
The documentary Beetles, Record Breakers makes use of 15 different terms to refer to beetles in less than 30 minutes (longhorn beetle, cellar beetle, stag beetle, burying beetle or gravediggers, sexton beetle, tiger beetle, bloody nose beetle, tortoise beetle, diving beetle, devil's coach horse, weevil, click beetle, malachite beetle, oil beetle, cockchafer), apart from mentioning other animals such as horseshoe bats or meadow brown butterflies.
Skeletons excavated from the Coburn Street Burial Ground (1750 to 1827 CE) in Cape Town, South Africa, were analyzed using stable isotope data in order to determine geographical histories and life histories. The people buried in this cemetery were assumed to be slaves and members of the underclass based on the informal nature of the cemetery; biomechanical stress analysis and stable isotope analysis, combined with other archaeological data, seem to support this supposition. Based on stable isotope levels, one study reported that eight Cobern Street Burial Ground individuals consumed a diet based on C4 (tropical) plants in childhood, then consumed more C3 plants, which were more common there later in their lives. Six of these individuals had dental modifications similar to those carried out by peoples inhabiting tropical areas known to be targeted by slavers who brought enslaved individuals from other parts of Africa to the colony. Based on this evidence, it was argued that these individuals represent enslaved persons from areas of Africa where C4 plants were consumed and who were brought to the Cape as laborers. These individuals were not assigned to a specific ethnicity, but similar dental modifications are carried out by the Makua, Yao, and Marav peoples. Four individuals were buried with no grave goods, in accordance with Muslim tradition, facing Signal Hill, which is a point of significance for local Muslims.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.